Zacks Investment Research
07 Oct 2026, 23:16 UTC · 2h ago
Ginkgo Bioworks Holdings, Inc. (DNA) Falls More Steeply Than Broader Market: What Investors Need to Know
Impact · against what's priced in
The article provides no new material catalysts for Ginkgo Bioworks, as the projected revenue collapse and EPS improvements are already reflected in the current analyst consensus. The recent stock price volatility follows a massive monthly rally and does not alter the fundamental outlook provided by the earnings estimates.
- DNA−0.20
No priced-in read yet





